{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:38:09Z","timestamp":1769557089804,"version":"3.49.0"},"reference-count":21,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Xijing Hospital discipline boost","award":["XJZT18MDT18"],"award-info":[{"award-number":["XJZT18MDT18"]}]},{"name":"Multidisciplinary comprehensive diagnosis and treatment project (key project)","award":["XJZT18MDT18"],"award-info":[{"award-number":["XJZT18MDT18"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Although recent trials started the use of neoadjuvant immunotherapy (NIT) in instability-high (MSI-H) or mismatch repair deficient (dMMR) early-stage or locally advanced colorectal cancer (LACRC), little data on the treatment strategy of NIT has been shown, and whether the tirelizumab mono-immune checkpoint inhibitor (ICI) can be used as NIT for patients with LACRC has not been reported as yet. In this study we report on a locally advanced ascending colon cancer case with a history of incomplete intestinal obstruction which achieved a pathologic complete response (pCR) after treated with Tirelizumab as NIT. A 32-year-old man was diagnosed with locally advanced ascending colon cancer with MSI-H and dMMR. An incomplete intestinal obstruction accompanied with hyperpyrexia occurred unexpectedly and was eased by symptomatic treatment. There was no peritonitis or other acute complications. NIT (three cycles of Tirelizumab) was suggested by the MDT board and partial response was achieved according to CT scanning, and pCR was further revealed by postoperative pathology. A ctDNA clearance confirmed the R0 resection and some immunotherapy related predictors were also detected using the NGS method. Our case study contributes to the evidence on the feasibility, efficacy, and safety of f Tirelizumab as a mono ICI for an optional neoadjuvant therapy in patients with MSI-H\/dMMR LACRC.<\/jats:p>","DOI":"10.3390\/jcm12010240","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:54:42Z","timestamp":1672282482000},"page":"240","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient\/MSI-High Ascending Colon Cancer: A Case Report"],"prefix":"10.3390","volume":"12","author":[{"given":"Yue","family":"Hei","sequence":"first","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengnan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3991-3750","authenticated-orcid":false,"given":"Hongmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi\u2019an 710032, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"795972","DOI":"10.3389\/fimmu.2022.795972","article-title":"Neoadjuvant immunotherapy for msi-h\/dmmr locally advanced colorectal cancer: New strategies and unveiled opportunities","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.6004\/jnccn.2020.7558","article-title":"Neoadjuvant immunotherapy-based systemic treatment in mmr-deficient or msi-high rectal cancer: Case series","volume":"18","author":"Demisse","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in mmr-proficient and mmr-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1711650","DOI":"10.1080\/2162402X.2020.1711650","article-title":"Pd-1 blockade in neoadjuvant setting of dna mismatch repair-deficient\/microsatellite instability-high colorectal cancer","volume":"9","author":"Liu","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"Pd-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: First approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"926480","DOI":"10.3389\/fonc.2022.926480","article-title":"Pathological complete response in mmr-deficient\/msi-high and kras-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jso.26771","article-title":"Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients","volume":"125","author":"Ni","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1078-0432.CCR-19-3728","article-title":"Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy","volume":"26","author":"Cercek","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2110","DOI":"10.1002\/onco.13955","article-title":"Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced msi-h\/dmmr rectal cancer","volume":"26","author":"Trojan","year":"2021","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1663108","DOI":"10.1080\/2162402X.2019.1663108","article-title":"Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab","volume":"8","author":"Zhang","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"913483","DOI":"10.3389\/fimmu.2022.913483","article-title":"Efficacy and safety of neoadjuvant monoimmunotherapy with pd-1 inhibitor for dmmr\/msi\u2043h locally advanced colorectal cancer: A single-center real-world study","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, Y., Yang, L., Bao, H., Fan, X., Xia, F., Wan, J., Shen, L., Guan, Y., Bao, H., and Wu, X. (2021). Utility of ctdna in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003741"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.21037\/tcr-21-2501","article-title":"Immune checkpoint inhibitor-induced colitis complicated with inflammatory intestinal obstruction: A case report and literature review","volume":"11","author":"Tan","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.21037\/atm-22-124","article-title":"The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy","volume":"10","author":"Wu","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yang, Z., Zhang, X., Zhang, J., Gao, J., Bai, Z., Deng, W., Chen, G., An, Y., Liu, Y., and Wei, Q. (2022). Rationale and design of a prospective, multicenter, phase ii clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (ncrt-pd1-larc trial). BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09554-9"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13304-019-00697-2","article-title":"Do microsatellite instability (msi) and deficient mismatch repair (dmmr) affect the pathologic complete response (pcr) in patients with rectal cancer who received neoadjuvant treatment?","volume":"72","author":"Acar","year":"2020","journal-title":"Updat. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41698-020-00132-5","article-title":"Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer","volume":"4","author":"Ye","year":"2020","journal-title":"NPJ Precis Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1526613","DOI":"10.1080\/2162402X.2018.1526613","article-title":"Integrated analysis of the immunological and genetic status in and across cancer types: Impact of mutational signatures beyond tumor mutational burden","volume":"7","author":"Budczies","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/cjp2.285","article-title":"A combination of stromal pd-l1 and tumoral nuclear \u03b2-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma","volume":"8","author":"Takahashi","year":"2022","journal-title":"J. Pathol. Clin. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/240\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:54:33Z","timestamp":1760147673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12010240"],"URL":"https:\/\/doi.org\/10.3390\/jcm12010240","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]}}}